<DOC>
	<DOCNO>NCT02538536</DOCNO>
	<brief_summary>This Phase 2 , open-label , single-arm study safety tolerability PBI-4050 800 mg daily oral administration 40 adult patient IPF .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Tolerability PBI-4050 Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description>This Phase 2 multi-centre study perform 6 Canadian site . It open-label , single-arm study patient Idiopathic Pulmonary Fibrosis ( IPF ) age 40 year old . The duration study participation approximately 20 week patient comprises 6 study visit .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>1 . Patient adult age 40 year old 2 . Patient sign write informed consent . 3 . Patient diagnose IPF accord recent guideline IPF diagnosis management release American Thoracic Society ( ATS ) , European Respiratory Society ( ERS ) , Japanese Respiratory Society ( JRS ) , Latin American Thoracic Association ( ALAT ) . 4 . Female patient childbearing potential must negative urine pregnancy test agree use adequate birth control screen throughout study 30 day last study drug administration . 5 . If male patient vasectomize least 6 month screen partner woman childbearing potential , must willing use acceptable contraceptive method throughout study 30 day last study drug administration . 1 . Patient known diagnosis respiratory disorder IPF . 2 . Substantial emphysema high resolution computer tomography ( HRCT ) degree emphysema great fibrosis . 3 . Patient active smoker . 4 . Patient evidence active infection . 5 . Patients currently history cancer , except basal cell carcinoma squamous cell carcinoma skin . 6 . Patient concurrent medical psychological condition , investigator 's opinion , may compromise patient 's ability participate study give inform consent , may complicate evaluation study drug . 7 . Patient receive another investigational treatment IPF screen and/or plan receive investigational treatment IPF current study . 8 . Patient chronic hepatitis significantly elevate liver enzyme level , define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5 × upper limit normal ( ULN ) total bilirubin ULN . 9 . Female patient pregnant , breastfeeding , plan pregnancy course study . 10 . Woman childbearing potential unwilling use adequate birth control throughout duration study . 11 . Patient participate investigational clinical trial last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>